Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine

View ORCID ProfileTal Patalon, Yaki Saciuk, Asaf Peretz, Galit Perez, Yoav Lurie, Yasmin Maor, View ORCID ProfileSivan Gazit
doi: https://doi.org/10.1101/2022.02.25.22271494
Tal Patalon
1Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, 68125, Israel
2Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Israel
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tal Patalon
  • For correspondence: patalon_t{at}mac.org.il
Yaki Saciuk
1Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, 68125, Israel
MPH MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asaf Peretz
2Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Israel
3Internal Medicine COVID-19 Ward, Samson Assuta Ashdod University Hospital, Ashdod Israel
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Galit Perez
2Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Israel
MN MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoav Lurie
4Liver unit, Shaare Zedek City Center Campus, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasmin Maor
5Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
6Infectious Disease Unit, Edith Wolfson Medical Centre, Holon, Israel
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivan Gazit
1Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, 68125, Israel
2Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Israel
MD MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sivan Gazit
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has yet to be sufficiently researched, while global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received three doses of the vaccine, we found that the effectiveness in each month since vaccination decreased significantly. Compared to those vaccinated early, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration and should prompt policy discussion as to additional booster doses and vaccine development.

Competing Interest Statement

YM received lecture fees and a quality grant from Pfizer. All other authors declare they have no conflict of interest.

Funding Statement

There was no external funding for the project.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the MHS (Maccabi Healthcare Services) Institutional Review Board. Due to the retrospective design of the study, informed consent was waived by the IRB, as all identifying details of the participants were removed before computational analysis.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

According to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data should be referred to KSM, Maccabi Healthcare Services Research and Innovation Center.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 26, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
Tal Patalon, Yaki Saciuk, Asaf Peretz, Galit Perez, Yoav Lurie, Yasmin Maor, Sivan Gazit
medRxiv 2022.02.25.22271494; doi: https://doi.org/10.1101/2022.02.25.22271494
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
Tal Patalon, Yaki Saciuk, Asaf Peretz, Galit Perez, Yoav Lurie, Yasmin Maor, Sivan Gazit
medRxiv 2022.02.25.22271494; doi: https://doi.org/10.1101/2022.02.25.22271494

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3284)
  • Dentistry and Oral Medicine (362)
  • Dermatology (275)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1166)
  • Epidemiology (13346)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5137)
  • Geriatric Medicine (480)
  • Health Economics (781)
  • Health Informatics (3260)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (428)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14615)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4907)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4196)
  • Public and Global Health (7488)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (479)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (203)